SCHEMBL3312265

SCHEMBL3312265

CC1CCN(C(=O)c2ccc3[nH]c4c(c3c2)CN(C(=O)OC(C)(C)C)CC4)CC1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR1 P21554 1/20 0.66
CNR2 P34972 1/20 0.60
KMT2A Q03164 3/20 0.52
MAPT P10636 3/20 0.52
SMN1; SMN2 Q16637 2/20 0.52
MEN1 O00255 2/20 0.52
HTT P42858 1/20 0.52
NPSR1 Q6W5P4 1/20 0.52
LMNA P02545 3/20 0.51
PABPC1 P11940 1/20 0.51
ATM Q13315 1/20 0.51
BAZ2B Q9UIF8 9/20 0.47
TRPV1 Q8NER1 1/20 0.45
KDM4E B2RXH2 2/20 0.45
POLB P06746 2/20 0.45
ALDH1A1 P00352 1/20 0.45
ALOX15 P16050 1/20 0.45
MAPK1 P28482 1/20 0.45
HSD17B10 Q99714 1/20 0.45
TDP1 Q9NUW8 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13329597 0.89 CNR1 (0.55) CNR1CNR2KMT2AMAPTSMN1; SMN2
SCHEMBL3310252 0.86 CNR1 (0.73) CNR1CNR2KMT2AMAPTSMN1; SMN2
SCHEMBL3310242 0.86 LMNA (0.50) CNR1CNR2MAPTSMN1; SMN2LMNA
SCHEMBL13360750 0.86 CNR1 (0.65) CNR1CNR2KMT2AMAPTSMN1; SMN2
SCHEMBL3312381 0.85 LMNA (0.57) KMT2AMAPTSMN1; SMN2LMNAPABPC1
SCHEMBL3305724 0.84 LMNA (0.50) CNR1MAPTSMN1; SMN2LMNAPABPC1
SCHEMBL61377 0.83 MEN1 (0.56) KMT2AMAPTSMN1; SMN2MEN1NPSR1
SCHEMBL13329249 0.83 CNR1 (0.74) CNR1CNR2KMT2AMAPTSMN1; SMN2
SCHEMBL3311717 0.82 CNR1 (0.73) CNR1CNR2KMT2AMAPTSMN1; SMN2
SCHEMBL30228387 0.81 TRPV1 (0.59) SMN1; SMN2LMNAPABPC1ATMBAZ2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100113502-A1 Novel Tetrahydro-1H-Pyrido[4,3-b] Indole Derivatives as CB1 Receptor Ligands ASTRAZENECA AB (SE) 2010-05-06 US disclosed
US-20100113502-A1 Novel Tetrahydro-1H-Pyrido[4,3-b] Indole Derivatives as CB1 Receptor Ligands ASTRAZENECA AB (SE) 2010-05-06 US disclosed
US-20100113502-A1 Novel Tetrahydro-1H-Pyrido[4,3-b] Indole Derivatives as CB1 Receptor Ligands ASTRAZENECA AB (SE) 2010-05-06 US disclosed
EP-1863810-A1 NOVEL TETRAHYDRO-1H-PYRIDO [4,3-b] INDOLE DERIVATIVES AS CB1' RECEPTOR LIGANDS AstraZeneca AB (SE) 2007-12-12 EP disclosed
WO-2006101434-A1 NOVEL TETRAHYDRO-1H-PYRIDO [4,3-b] INDOLE DERIVATIVES AS CB1’ RECEPTOR LIGANDS ASTRAZENECA AB (SE) 2006-09-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100113502-A1 Novel Tetrahydro-1H-Pyrido[4,3-b] Indole Derivatives as CB1 Receptor Ligands CNR1, CNR2, OPRL1 CNR1 1/4885CNR2 2/4885KMT2A 2274/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.